Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants
Status:
Completed
Trial end date:
2017-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the bioavailability of dexlansoprazole from a 30
milligram (mg) or 60 mg delayed-release capsule manufactured at Takeda GmbH Plant
Oranienburg, Germany (TOB) relative to that of dexlansoprazole from a 30 mg or 60 mg capsule
manufactured at Takeda Pharmaceutical Company Ltd. (Osaka, Japan) (TPC).